RPRX
Royalty Pharma plc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Royalty Pharma plc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Feb 11 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 11 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Royalty Pharma plc
67.34
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Royalty Pharma plc's 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Royalty Pharma plc's 6 closest co-movers, 1 shares that code.
| Manager | Value | % base | |
|---|---|---|---|
| Morgan Stanley | $2.4B | 11.68% | −1.47% |
| Capital International Investors | $2.0B | 9.59% | +0.77% |
| BlackRockindex-like | $1.6B | 7.57% | +7.43% |
| FMR | $1.4B | 6.67% | −2.54% |
| State Streetindex-like | $691.8M | 3.36% | +12.27% |
| Manager | Value | % base | |
|---|---|---|---|
| Morgan Stanley | $2.4B | 11.68% | −1.47% |
| Capital International Investors | $2.0B | 9.59% | +0.77% |
| BlackRockindex-like | $1.6B | 7.57% | +7.43% |
| FMR | $1.4B | 6.67% | −2.54% |
| State Streetindex-like | $691.8M | 3.36% | +12.27% |
Linked news
Bull2
Bear2
Expected move
Inputs8Q avg ±3.2%·×0.41·cheap
straddle ±5.4%
spot 67.18exp Nov 20ATM strike 67.5ATM straddle 4.28IV 33%